Is It Time to Sell MercadoLibre?
MercadoLibre (NASDAQ:MELI) has earned a reputation for being not dissimilar…
Sell
28
NVO Quote, Financials, Valuation and Earnings
Last price:
$72.58
Seasonality move
:
3.39%
Day range:
$72.02 - $73.14
52-week range:
$57.00 - $148.15
Dividend yield:
2.3%
P/E ratio:
21.34x
P/S ratio:
7.37x
P/B ratio:
15.93x
Volume:
6.9M
Avg. volume:
10.8M
1-year change:
-48.51%
Market cap:
$320.1B
Revenue:
$42.1B
EPS (TTM):
$3.38
Analysts' Opinion
-
Consensus RatingNovo Nordisk AS has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 4 Buy ratings, 4 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $91.05, Novo Nordisk AS has an estimated upside of 26.39% from its current price of $72.04.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $61.26 representing 14.96% downside risk from its current price of $72.04.
Fair Value
-
According to the consensus of 9 analysts, Novo Nordisk AS has 26.39% upside to fair value with a price target of $91.05 per share.
NVO vs. S&P 500
-
Over the past 5 trading days, Novo Nordisk AS has overperformed the S&P 500 by 3.98% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Novo Nordisk AS does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Novo Nordisk AS has grown year-over-year revenues for 19 quarters straight. In the most recent quarter Novo Nordisk AS reported revenues of $11B.
Earnings Growth
-
Novo Nordisk AS has grown year-over-year earnings for 11 quarters straight. In the most recent quarter Novo Nordisk AS reported earnings per share of $0.92.
Enterprise value:
331.3B
EV / Invested capital:
8.88x
Price / LTM sales:
7.37x
EV / EBIT:
16.55x
EV / Revenue:
7.60x
PEG ratio (5yr expected):
1.29x
EV / Free cash flow:
30.83x
Price / Operating cash flow:
29.88x
Enterprise value / EBITDA:
14.96x
Gross Profit (TTM):
$36.8B
Return On Assets:
25.78%
Net Income Margin (TTM):
34.52%
Return On Equity:
84.88%
Return On Invested Capital:
53.78%
Operating Margin:
49.68%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $26.4B | $35.5B | $43.6B | $9.5B | $11B | |
| Gross Profit | $22.2B | $30.1B | $36.8B | $8.1B | $9.2B | |
| Operating Income | $11.3B | $15.9B | $19.4B | $4.6B | $5.5B | |
| EBITDA | $11.7B | $18.2B | $22.1B | $5.4B | $6.5B | |
| Diluted EPS | $1.90 | $2.90 | $3.38 | $0.83 | $0.92 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $9.7B | $13B | $16.7B | $16.8B | $25.3B | |
| Total Assets | $22.3B | $29.6B | $36.6B | $43.2B | $71B | |
| Current Liabilities | $11.4B | $14.3B | $19.3B | $24B | $34.3B | |
| Total Liabilities | $13.1B | $19.6B | $24.9B | $28.9B | $50.9B | |
| Total Equity | $9.2B | $10B | $11.7B | $14.3B | $20.1B | |
| Total Debt | $1.5B | $3.8B | $3.7B | $3.9B | $17.2B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $11.9B | $13.6B | $18.9B | $2.1B | $3.5B | |
| Cash From Investing | -$4.2B | -$4.8B | -$20.2B | $576.2M | -$940.8M | |
| Cash From Financing | -$7.4B | -$10B | $5.9B | -$3.8B | $768.5M | |
| Free Cash Flow | $9.4B | $7.3B | $10.7B | $772.7M | $1.4B | |
NVO
Sector
Market Cap
$320.1B
$33.6M
Price % of 52-Week High
48.63%
45.68%
Dividend Yield
2.3%
0%
Shareholder Yield
2.36%
-0.66%
1-Year Price Total Return
-48.51%
-38.85%
Beta (5-Year)
0.662
0.633
Dividend yield:
2.3%
Annualized payout:
$1.45
Payout ratio:
47.98%
Growth streak:
5 years
Technicals
8-day SMA
Buy
Level
$70.39
200-day SMA
Sell
Level
$94.72
Bollinger Bands (100)
Sell
Level
65.45 - 84.35
Chaikin Money Flow
Buy
Level
338.6M
20-day SMA
Buy
Level
$68.05
Relative Strength Index (RSI14)
Buy
Level
58.87
ADX Line
Buy
Level
15.26
Williams %R
Sell
Level
-10.989
50-day SMA
Buy
Level
$66.35
MACD (12, 26)
Buy
Level
1.33
25-day Aroon Oscillator
Buy
Level
48
On Balance Volume
Neutral
Level
29.6M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (6.9834)
Buy
CA Score
(Annual)
Level (0.5179)
Buy
Beneish M-Score
(Annual)
Level (-2.48)
Sell
Momentum Score
Level (2)
Buy
Ohlson Score
Level (-1.1143)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Stock Forecast FAQ
In the current month, NVO has received 4 Buy ratings 4 Hold ratings, and 1 Sell ratings. The NVO average analyst price target in the past 3 months is $91.05.
-
Where Will Novo Nordisk AS Stock Be In 1 Year?
According to analysts, the consensus estimate is that Novo Nordisk AS share price will rise to $91.05 per share over the next 12 months.
-
What Do Analysts Say About Novo Nordisk AS?
Analysts are divided on their view about Novo Nordisk AS share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Novo Nordisk AS is a Sell and believe this share price will drop from its current level to $61.26.
-
What Is Novo Nordisk AS's Price Target?
The price target for Novo Nordisk AS over the next 1-year time period is forecast to be $91.05 according to 9 Wall Street analysts, 4 of them rate the stock a Buy, 1 rates the stock a Sell, and 4 analysts rate the stock a Hold.
-
Is NVO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Novo Nordisk AS is a Leans Bullish. 4 of 9 analysts rate the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of NVO?
You can purchase shares of Novo Nordisk AS via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Novo Nordisk AS shares.
-
What Is The Novo Nordisk AS Share Price Today?
Novo Nordisk AS was last trading at $72.58 per share. This represents the most recent stock quote for Novo Nordisk AS. Yesterday, Novo Nordisk AS closed at $72.04 per share.
-
How To Buy Novo Nordisk AS Stock Online?
In order to purchase Novo Nordisk AS stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Tesla Stock High Risk or High Reward?
EV-making supergiant Tesla, Inc. (NASDAQ:TSLA) is going through a difficult…
Why Did Chase Coleman Buy TSM?
Billionaire Chase Coleman of Tiger Global Management has built a…
Stock Ideas
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 48x
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Sell
42
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
76
SBET alert for Jun 5
SharpLink Gaming [SBET] is down 27.96% over the past day.
Buy
80
GWRE alert for Jun 5
Guidewire Software [GWRE] is up 0.78% over the past day.
Buy
70
ZLAB alert for Jun 5
Zai Lab [ZLAB] is up 1.27% over the past day.
